A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program

Novakovic, Daniel; Cheng, Alan T. L.; Yvonne Zurynski; Booy, Robert; Walker, Paul J.; Berkowitz, Robert; Harrison, Henley; Black, Robert; Perry, Christopher; Vijayasekaran, Shyan; Wabnitz, David; Burns, Hannah; Tabrizi, Sepehr N.; Garland, Suzanne M.; Elliott, Elizabeth; Brotherton, Julia M. L.; Zurynski, Yvonne
January 2018
Journal of Infectious Diseases;1/15/2018, Vol. 217 Issue 2, p208
Academic Journal
journal article
Background: Recurrent respiratory papillomatosis is a rare but morbid disease caused by human papillomavirus (HPV) types 6 and 11. Infection is preventable through HPV vaccination. Following an extensive quadrivalent HPV vaccination program (females 12-26 years in 2007-2009) in Australia, we established a method to monitor incidence and demographics of juvenile-onset recurrent respiratory papillomatosis (JORRP) cases.Methods: The Australian Paediatric Surveillance Unit undertakes surveillance of rare pediatric diseases by contacting practitioners monthly. We enrolled pediatric otorhinolaryngologists and offered HPV typing. We report findings for 5 years to end 2016.Results: The average annual incidence rate was 0.07 per 100000. The largest number of cases was reported in the first year, with decreasing annual frequency thereafter. Rates declined from 0.16 per 100000 in 2012 to 0.02 per 100000 in 2016 (P = .034). Among the 15 incident cases (60% male), no mothers were vaccinated prepregnancy, 20% had maternal history of genital warts, and 60% were first born; 13/15 were born vaginally. Genotyped cases were HPV-6 (n = 4) or HPV-11 (n = 3).Conclusion: To our knowledge, this is the first report internationally documenting decline in JORRP incidence in children following a quadrivalent HPV vaccination program.


Related Articles

  • Potential impact of the human papillomavirus vaccine on the incidence proportion of genital warts in French women (EFFICAE study): a multicentric prospective observational study. Judlin, Philippe; Jacquard, Anne-Carole; Carcopino, Xavier; Aubin, François; Dahlab, André; Mistretta, Frédéric; Not, Didier; Boelle, Pierre-Yves; Aynaud, Olivier; Soubeyrand, Benoît // Sexual Health (14485028);2016, Vol. 13 Issue 1, p49 

    Unlabelled: Background The objective was to evaluate the effect of a HPV vaccination program on the incidence proportion of a proxy, genital warts (GW), in women in France.Methods: The number of primary GW cases was prospectively recorded over two 4-month periods before...

  • Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis. Rosenberg, Tine; Philipsen, Bahareh B; Mehlum, Camilla S; Dyrvig, Anne-Kirstine; Wehberg, Sonja; Chirilǎ, Magdalena; Godballe, Christian // Journal of Infectious Diseases;3/15/2019, Vol. 219 Issue 6, p1016 

    Background: Recurrent respiratory papillomatosis is a benign condition caused by human papillomavirus (HPV). Surgery is the mainstay of treatment, but numerous adjuvant therapies have been applied to improve surgical outcome. Recently, HPV vaccination has been introduced, but only...

  • Addressing Health Inequalities in the Delivery of the Human Papillomavirus Vaccination Programme: Examining the Role of the School Nurse. Boyce, Tammy; Holmes, Alison; Fielding, Richard // PLoS ONE;Sep2012, Vol. 7 Issue 9, Special section p1 

    Background: HPV immunisation of adolescent girls is expected to have a significant impact in the reduction of cervical cancer. UK The HPV immunisation programme is primarily delivered by school nurses. We examine the role of school nurses in delivering the HPV immunisation programme and their...

  • When the Patient Asks. Stabb, Jessica E.; Buckley, Rebecca // JAAPA: Journal of the American Academy of Physician Assistants (;Jan2011, Vol. 24 Issue 1, p53 

    The article provides an answer to the question related to the benefits of human papillomavirus vaccine.

  • Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013. Cameron, Ross L.; Kavanagh, Kimberley; Pan, Jiafeng; Love, John; Cuschieri, Kate; Robertson, Chris; Ahmed, Syed; Palmer, Timothy; Pollock, Kevin G. J. // Emerging Infectious Diseases;Jan2016, Vol. 22 Issue 1, p56 

    In 2008, a national human papillomavirus (HPV) immunization program using a bivalent vaccine against HPV types 16 and 18 was implemented in Scotland along with a national surveillance program designed to determine the longitudinal effects of vaccination on HPV infection at the population level....

  • US Panel Backs HPV Vaccine for Males.  // Clinical Infectious Diseases;11/1/2009, Vol. 49 Issue 9, pii 

    The article reports on a vaccine developed by Merk & Co. Inc. for the prevention of human papillomavirus (HPV) infection that causes cervical cancer and genital warts. According to the Food and Drug Administration advisory panel in the U.S., Gardasil vaccine is safe and effective to prevent...

  • Comparing bivalent and quadrivalent HPV vaccines. Verheijen, René H. M. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/1/2011, Vol. 343 Issue 7825, p647 

    The author reflects on a national vaccination programme of human papillomavirus (HPV) conducted by the Department of health of Great Britain. He states that the programme was for 12-18 years of girls and under which cost of two vaccines, Cervarix and Gardasil, was compared. It informs that...

  • Leveraging machine learning-based approaches to assess human papillomavirus vaccination sentiment trends with Twitter data. Jingcheng Du; Jun Xu; Hsing-Yi Song; Cui Tao; Du, Jingcheng; Xu, Jun; Song, Hsing-Yi; Tao, Cui // BMC Medical Informatics & Decision Making;7/5/2017, Vol. 17, p63 

    Background: As one of the serious public health issues, vaccination refusal has been attracting more and more attention, especially for newly approved human papillomavirus (HPV) vaccines. Understanding public opinion towards HPV vaccines, especially concerns on social media, is of...

  • Human Papillomavirus Vaccination Coverage Among School Girls in a Demonstration Project - Botswana, 2013. Raesima, Mmakgomo Mimi; Forhan, Sara E.; Voetsch, Andrew C.; Hewitt, Shannon; Hariri, Susan; Wang, Susan A.; Pelletier, Andrew R.; Letebele, Mpho; Pheto, Tlhomamo; Ramogola-Masire, Doreen; El-Halabi, Shenaaz // MMWR: Morbidity & Mortality Weekly Report;10/16/2015, Vol. 64 Issue 40, p1147 

    What is already known on this topic? Human papillomavirus (HPV) infection is common and aggressive in persons infected with human immunodeficiency virus (HIV). With an HIV prevalence of 28% among females aged 15–49, cervical cancer is the leading cause of cancer death among women in...

  • EDITOR'S CHOICE. Why don't we know how much vaccines cost? Godlee, Fiona // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;10/1/2011, Vol. 343 Issue 7825, preceding p647 

    The article offers information on Global Alliance on Vaccines and Immunisation (GAVI) and its vaccination that makes healthy body and mind.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics